Shohei Tsuji
Overview
Explore the profile of Shohei Tsuji including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
157
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tsuji S, Hosokawa Y, Sato H, Tokioka K, Ikezono T
Cureus
. 2025 Feb;
17(1):e77659.
PMID: 39968444
Blowout fractures (BOFs) frequently result in early-onset diplopia, which often resolves spontaneously. Delayed diplopia is rare, and there are no reported cases of its sudden onset following a prolonged asymptomatic...
2.
Soma N, Uchida Y, Kouyama J, Naiki K, Usui N, Sato A, et al.
J Gastroenterol
. 2024 Oct;
60(1):96-106.
PMID: 39412575
Background: Covert hepatic encephalopathy (CHE) significantly impacts the quality of life and prognosis in patients with liver cirrhosis. This study aims to analyze the prevalence and risk factors of CHE...
3.
Tsuji S, Kudo U, Takahashi K, Nakamura S, Shimazawa M
J Neurooncol
. 2024 Aug;
170(2):319-329.
PMID: 39141257
Purpose: Glioblastoma (GBM), characterized by astrocytic tumorigenesis, remains one of the most prognostically challenging tumor types. Targeting entire GBM microenvironment using novel therapeutic factors is currently desired investigation approach. In...
4.
Tsuji S, Kudo U, Hatakeyama R, Shoda K, Nakamura S, Shimazawa M
Biochem Biophys Res Commun
. 2024 Apr;
711:149897.
PMID: 38608433
Purpose: Dipeptidyl peptidase-4 (DPP-4) inhibitors are oral hypoglycemic drugs and are used for type II diabetes. Previous studies showed that DPP-4 expression is observed in several tumor types and DPP-4...
5.
Yamada S, Uchida Y, Kouyama J, Naiki K, Tsuji S, Uemura H, et al.
Hepatol Res
. 2024 Mar;
54(10):877-887.
PMID: 38517681
Aim: Patients with chronic hepatitis B virus (HBV) infection experiencing viral breakthrough (BTH) or partial response (PR) during lamivudine (LAM) or entecavir hydrate (ETV) administration often took ETV plus tenofovir...
6.
Uchida Y, Imai Y, Tsuji S, Uemura H, Kouyama J, Naiki K, et al.
Hepatol Res
. 2023 May;
53(9):815-828.
PMID: 37243512
Aim: To determine the outcomes concerning portal venous blood flow and portosystemic shunts in patients with decompensated cirrhosis due to hepatitis C virus (HCV) infection who achieved sustained viral response...
7.
Tsuji S, Nakamura S, Shoda K, Yamada T, Shimazawa M, Nakayama N, et al.
J Neurooncol
. 2022 Oct;
160(2):375-388.
PMID: 36308592
Purpose: The alkylating agent temozolomide (TMZ) has a significant impact on the prognosis of glioblastoma (GBM) patients. Therefore, maximizing TMZ efficacy is important for GBM treatment. Many reports have shown...
8.
Wang R, Alamin M, Tsuji S, Hara-Yamamura H, Hata A, Zhao B, et al.
Sci Total Environ
. 2022 Aug;
851(Pt 2):158310.
PMID: 36030862
The potential risk of SARS-CoV-2 in treated effluent from a wastewater treatment plant (WWTP) is concerned since SARS-CoV-2 is contained in wastewater during the COVID-19 outbreak. However, the removal of...
9.
Kajimoto Y, Kameda M, Kambara A, Kuroda K, Tsuji S, Nikaido Y, et al.
Front Neurol
. 2022 Apr;
13:866352.
PMID: 35481276
Objectives: Because the progression of idiopathic normal pressure hydrocephalus (iNPH) is partially irreversible, we hypothesized that early intervention would markedly improve its prognosis. To test this hypothesis, we retrospectively investigated...
10.
Shoda K, Tsuji S, Nakamura S, Egashira Y, Enomoto Y, Nakayama N, et al.
Cell Mol Neurobiol
. 2022 Apr;
43(2):879-892.
PMID: 35435536
Sodium-glucose transporter 2 (SGLT2) inhibitors are antidiabetic drugs affecting SGLT2. Recent studies have shown various cancers expressing SGLT2, and SGLT2 inhibitors attenuating tumor proliferation. We evaluated the antitumor activities of...